Debiopharm Group

Debiopharm Group is a biopharmaceutical development specialist based in Lausanne, Switzerland, focusing on in-licensing promising biologics and small molecule drug candidates for global registration. The group aims to maximize the commercial potential of its products through out-licensing agreements with pharmaceutical partners for sales and marketing. It operates multiple investment arms, including the Debiopharm Innovation Fund, which invests in early-stage companies within the biotechnology, diagnostics, and digital health sectors, focusing on smart data and biomarker development. This fund typically invests between $1 million and $10 million, seeking minority stakes and board representation in its portfolio companies. Additionally, Debiopharm Investment engages in private equity and real estate investments, targeting mature companies in IT security and renewable sectors, as well as residential and commercial properties primarily in Western Europe. With a commitment to long-term investments and active involvement in corporate governance, Debiopharm Group drives its portfolio companies toward successful market exits.

Past deals in Switzerland

BC Platforms

Series C in 2019
BC Platforms specializes in genomic data management solutions that aim to tackle significant healthcare challenges through the integration of genomics and information technology. The company's platform facilitates the flexible integration, secure analysis, and interpretation of molecular and clinical big data in a systematic and standardized manner. By providing robust tools for managing genomic data, BC Platforms supports researchers and healthcare professionals in deriving meaningful insights to advance precision medicine and improve patient outcomes.

Little Green House

Corporate Round in 2019
Little Green House have a vision to make our daycare a place where everyone is free to be who they are and to become who they want to be.

Kaiku Health

Series A in 2018
Kaiku Health Oy develops and delivers user-centered software solutions for patients, doctors, and nurses to communicate online. It develops a communication and follow-up solution for cancer patients to communicate with medical staff in Swedish, English, German, and Finnish languages. The company serves clinics and university hospitals in Finland, Sweden, and Switzerland. Kaiku Health Oy was formerly known as Netmedi Oy and changed its name to Kaiku Health Oy in September 2017. The company was founded in 2012 and is based in Helsinki, Finland. As of May 15, 2020, Kaiku Health Oy operates as a subsidiary of Elekta AB (publ).

BC Platforms

Series B in 2017
BC Platforms specializes in genomic data management solutions that aim to tackle significant healthcare challenges through the integration of genomics and information technology. The company's platform facilitates the flexible integration, secure analysis, and interpretation of molecular and clinical big data in a systematic and standardized manner. By providing robust tools for managing genomic data, BC Platforms supports researchers and healthcare professionals in deriving meaningful insights to advance precision medicine and improve patient outcomes.

Coorpacademy

Series B in 2016
Coorpacademy S.A., founded in 2013 and based in Lausanne, Switzerland, specializes in developing online training courses and innovative learning solutions, including massive open online courses (MOOCs). The company offers a learning experience platform that features a diverse catalog of training courses characterized by short, accessible sessions. This platform is designed to enhance digital learning for employees by providing customized content tailored to individual needs, making it easy for users to engage with the material at any time and across various mediums.

Coorpacademy

Series A in 2014
Coorpacademy S.A., founded in 2013 and based in Lausanne, Switzerland, specializes in developing online training courses and innovative learning solutions, including massive open online courses (MOOCs). The company offers a learning experience platform that features a diverse catalog of training courses characterized by short, accessible sessions. This platform is designed to enhance digital learning for employees by providing customized content tailored to individual needs, making it easy for users to engage with the material at any time and across various mediums.

BPA Solutions

Funding Round in 2013
BPA Solutions SA specializes in providing innovative business applications that enhance Microsoft SharePoint and Office 365. Founded in 2001 and headquartered in Yverdon-les-Bains, Switzerland, the company develops a range of solutions including BPA CRM for customer relationship management, BPA Quality for quality management, and BPA Risk for tracking business activities in complex environments. Additional offerings include BPA Project for project management, BPA Recruiting for candidate management, and Self-Service tools for process sharing. BPA Solutions also features a Solutions Suite to monitor critical business processes and mobile solutions, along with professional services such as training, consulting, and support. The company delivers its software on-premise, through private or Microsoft clouds, and in hybrid environments, serving clients globally.

Biocartis

Series E in 2013
Biocartis Group NV is a molecular diagnostics company that specializes in developing diagnostic solutions with a strong emphasis on oncology. The company’s proprietary Idylla platform utilizes real-time polymerase chain reaction technology to deliver critical molecular information that aids in treatment selection and monitoring. Biocartis offers a range of diagnostic tests, including solid biopsy tests for mutations such as BRAF, KRAS, and EGFR, as well as plasma liquid biopsy tests for ctKRAS and ctNRAS. In addition to its diagnostic offerings, the company collaborates with major pharmaceutical firms like AstraZeneca and Bristol-Myers Squibb to create companion diagnostics that enhance treatment efficacy in cancer care. Founded in 2007, Biocartis is headquartered in Mechelen, Belgium, and strives to improve personalized medical treatments through its innovative diagnostic systems.

Skioo

Venture Round in 2013
Skioo is a developer of a ski-lift ticketing platform designed to streamline the booking of ski adventures. The company provides the Skioo Pass, which grants skiers instant access to a wide network of ski partner resorts in Switzerland and beyond. By synchronizing its platform with the systems of ski resorts and lift operators, Skioo enables users to conveniently purchase ski tickets from a single interface. Additionally, the Skioo App fosters a community among skiing enthusiasts and offers valuable information and features to enhance the skiing experience. Founded in 2019 as part of the Skitude group, Skioo is supported by key technology partners, including Skidata AG and Team Axess AG.

KeyLemon

Series A in 2013
KeyLemon S.A. develops face recognition technology. The company was founded in 2008 and is based in Martigny, Switzerland. As of February 22, 2018, KeyLemon S.A. operates as a subsidiary of ams AG.

Diagnoplex

Venture Round in 2013
Diagnoplex has been founded in 2005 supported by seed financing fron the Novartis Forschungsstiftung, Swiss Confederation CTI project, Canton de Vaud FIT and the Gebert Rüf Stiftung. The company has performed a 140 patient prospective pilot study demonstrating technical and clinical feasibility of its colorectal cancer screening test COLOX as well as its high sensitivity and specificity.

Urturn

Series A in 2013
Urturn is the new social platform for self-expression. Both on the Desktop and as an iPhone app, users are able to spontaneously capture moments of inspiration on-the-fly! The ever-growing library of Expression can be instantly personalised in all kinds of ways and the unique 'Your Turn' button lets users take inspiration from or join in with online movements in rich and interactive way. Spontaneous, engaging and fun, Urturn is the next natural step for social media. It's Urturn...

Compliant Concept

Venture Round in 2013
Compliant Concept is a spinoff of the Empa and the ETH Zurich. They develop intelligent bed systems for the treatment and prevention of pressure ulcers. compliant concept is a spin-off of ETH Zurich and Empa, with its roots in Empa's Laboratory for Mechanics for Modeling and Simulation. Their goal is to make the care of hospital patients and nursing home residents safer, more efficient and more comfortable.

Spinomix

Series A in 2013
Spinomix is a Swiss technology platform company providing innovative sample processing solutions to the life sciences sector. Based at the Ecole Polytechnique Fédérale de Lausanne (EPFL), the company is building the new gold standard for the processing of biochemical substances. Its products capture and extract samples at a quality and efficiency far superior to current practice, thus enabling more efficient diagnostics. The company’s main focus is on applications which are critical for treatment decisions in a variety of human diseases. Other applications target markets such as animal health and food safety. Spinomix’ products MagPhase™ and FibroTrap™ improve the accuracy and time taken to obtain meaningful results from samples that are highly heterogeneous and notoriously difficult to analyse (e.g. blood, urine, swabs and food matrices). Today many aspects of sample processing are still labour and time intensive. Therefore, there is a significant opportunity for Spinomix’s technologies to streamline the process. They are targeting double-digit growth markets such as nucleic acids extraction, believed to be worth $2 billion; cell separation growing to over $2.5 billion; food safety at over $2 billion; and molecular diagnostics for infectious diseases estimated at $2.7 billion. Their current approach is to concentrate on product innovation and market validation. They have collaboration agreements in place and are conducting validation programs of their products with key market players in research and industry. Their goal is to develop these collaborations into strategic commercial partnerships to license their products.

Biocartis

Series D in 2012
Biocartis Group NV is a molecular diagnostics company that specializes in developing diagnostic solutions with a strong emphasis on oncology. The company’s proprietary Idylla platform utilizes real-time polymerase chain reaction technology to deliver critical molecular information that aids in treatment selection and monitoring. Biocartis offers a range of diagnostic tests, including solid biopsy tests for mutations such as BRAF, KRAS, and EGFR, as well as plasma liquid biopsy tests for ctKRAS and ctNRAS. In addition to its diagnostic offerings, the company collaborates with major pharmaceutical firms like AstraZeneca and Bristol-Myers Squibb to create companion diagnostics that enhance treatment efficacy in cancer care. Founded in 2007, Biocartis is headquartered in Mechelen, Belgium, and strives to improve personalized medical treatments through its innovative diagnostic systems.

Skioo

Seed Round in 2012
Skioo is a developer of a ski-lift ticketing platform designed to streamline the booking of ski adventures. The company provides the Skioo Pass, which grants skiers instant access to a wide network of ski partner resorts in Switzerland and beyond. By synchronizing its platform with the systems of ski resorts and lift operators, Skioo enables users to conveniently purchase ski tickets from a single interface. Additionally, the Skioo App fosters a community among skiing enthusiasts and offers valuable information and features to enhance the skiing experience. Founded in 2019 as part of the Skitude group, Skioo is supported by key technology partners, including Skidata AG and Team Axess AG.

Searchbox

Series B in 2012
Searchbox is a software company specializing in search technologies, with strong areas of expertise in cognitive sciences, data mining and computer sciences. Through its innovative technologies, Searchbox fundamentally changes the way people interact and consume information. Through highly customizable cloud based search solutions and plugins for Solr, these technologies are readily available for usage with a minimal amount of tinkering.

Tweasy

Venture Round in 2012
Tweasy helps businesses stay close to their customers and grow strong and profitable relationships. The Tweasy application brings together all the news, promotions, surveys and information generated by businesses, clubs and associations to help them communicate.

Biocartis

Series C in 2011
Biocartis Group NV is a molecular diagnostics company that specializes in developing diagnostic solutions with a strong emphasis on oncology. The company’s proprietary Idylla platform utilizes real-time polymerase chain reaction technology to deliver critical molecular information that aids in treatment selection and monitoring. Biocartis offers a range of diagnostic tests, including solid biopsy tests for mutations such as BRAF, KRAS, and EGFR, as well as plasma liquid biopsy tests for ctKRAS and ctNRAS. In addition to its diagnostic offerings, the company collaborates with major pharmaceutical firms like AstraZeneca and Bristol-Myers Squibb to create companion diagnostics that enhance treatment efficacy in cancer care. Founded in 2007, Biocartis is headquartered in Mechelen, Belgium, and strives to improve personalized medical treatments through its innovative diagnostic systems.

Biocartis

Series B in 2010
Biocartis Group NV is a molecular diagnostics company that specializes in developing diagnostic solutions with a strong emphasis on oncology. The company’s proprietary Idylla platform utilizes real-time polymerase chain reaction technology to deliver critical molecular information that aids in treatment selection and monitoring. Biocartis offers a range of diagnostic tests, including solid biopsy tests for mutations such as BRAF, KRAS, and EGFR, as well as plasma liquid biopsy tests for ctKRAS and ctNRAS. In addition to its diagnostic offerings, the company collaborates with major pharmaceutical firms like AstraZeneca and Bristol-Myers Squibb to create companion diagnostics that enhance treatment efficacy in cancer care. Founded in 2007, Biocartis is headquartered in Mechelen, Belgium, and strives to improve personalized medical treatments through its innovative diagnostic systems.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.